Vapor, this is all you need to know about why NEU's valuation was increased by Bell Potter.
Clinicians Clinicians support trofinetide uptake
MST has undertaken discussions with specialist clinicians regarding
the results of the Phase 3 trials in Rett (RTT) Syndrome. The
clinicians’ support of both the strength of Phase 3 trial results and
trofinetide’s potential role in patient management has given
confidence to increase NEU’s valuation to A$6.21ps (prev $5.05).
Valuation, Key Risks and Sensitivities
We value NEU at $6.21 per share on a 12-month forward risk-adjusted DCF basis (previously $5.05ps).
Following discussions with clinicians, we have increased market share across the different markets.
Averaged
market share across the US, EU and ROW now peaks at 21% (prev15%). The probability of approval of 25% for
NNZ-2591 and other valuation assumptions are unchanged
Vapor, this is all you need to know about why NEU's valuation...
-
- There are more pages in this discussion • 11,822 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.27 |
Change
1.000(8.15%) |
Mkt cap ! $1.696B | |||
| Open | High | Low | Value | Volume |
| $12.95 | $13.39 | $12.79 | $9.854M | 751.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2545 | $13.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.29 | 1443 | 2 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |